Details for Patent: 9,844,567
✉ Email this page to a colleague
Which drugs does patent 9,844,567 protect, and when does it expire?
Patent 9,844,567 protects LOKELMA and is included in one NDA.
This patent has forty-six patent family members in twenty-nine countries.
Summary for Patent: 9,844,567
| Title: | Microporous zirconium silicate for the treatment of hyperkalemia |
| Abstract: | The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. |
| Inventor(s): | Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX) |
| Assignee: | ZS PHARMA, INC. (Coppell, TX) |
| Application Number: | 14/321,659 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,844,567 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
More… ↓ |
Drugs Protected by US Patent 9,844,567
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-001 | May 18, 2018 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA IN ADULTS | ⤷ Subscribe | ||||
| Astrazeneca | LOKELMA | sodium zirconium cyclosilicate | FOR SUSPENSION;ORAL | 207078-002 | May 18, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF HYPERKALEMIA IN ADULTS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,844,567
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2673237 | ⤷ Subscribe | 300976 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2673237 | ⤷ Subscribe | LUC00111 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2673237 | ⤷ Subscribe | PA2019010 | Lithuania | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
